14 November 2018
Dr Antonio Páez, Grifols Medical Director and Head of the AMBAR Clinical Program, confirmed that "the analysis of AMBAR data in moderate patients has shown positive, highly relevant results in a cohort of patients suffering from moderate Alzheimer’s disease."
The combination of Plasmapheresis, a well known and safe procedure used in plasma exchange, with Albutein® (Albumin) may offer a new treatment pathway for the illness.
Fundació ACE in Barcelona and ...
14 November 2018
Ahead Therapeutics, a company promoted by ZBM Business Connect in 2017, is preparing for a new funding round to start the clinical trials. The first round amounted to a total of 2 million euros.
The biotech aims to develop new drugs against autoimmune diseases (type 1 diabetes, multiple sclerosis, celiac disease, pemphigus and thyroiditis). Its technology comes from the Germans Trias i Pujol Research Institute (IGTP), the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and the Catalan Institution for Research and Advanced Studies (ICREA).
ZBM Business Connect, division of ZBM Patents & Trademarks and a CataloniaBio & HealthTech member ...
13 November 2018
FreeOx Biotech, a spin-out of Hospital Clinic Barcelona-IDIBAPS created in 2017 that is developing a new class of neuroprotective drugs, has closed its first round of funding with €500,000 from private investors Montserrat Esteve and Francisco Javier Alsina.
The biotech member of CataloniaBio & HealthTech has two highly promising molecules in its pipeline to treat stroke and other diseases of the central nervous system (CNS): Ox-01 and Ox-02.
With this funding, they will carry out formulation and preclinical trials with in vivo testing on Ox-02. Also, “it will allow us to prepare to start phase III clinical ...
12 November 2018
iVascular, a CataloniaBio & HealthTech member, has acquired 10% of the shares of the American start-up NaviGate Cardiac Structures for €8,7 million. With this purchase, iVascular becomes part of the Board of Directors of the Navigate.
The agreement between both companies, contemplates the joint development of a new product: the tricuspid valve with percutaneous access. Clinical studies are currently underway in the United States and Europe to analyze the efficacy and safety of this valve, that is estimated to be ready for clinical application by 2020.
iVascular has its headquarters in Sant Vicenç dels Horts (Barcelona).
7 November 2018
Reig Jofre has inaugurated the expansion of its plant in Toledo, which has a total of 15,200 square metres. This additional space is used for a new line specialising in penicillin-derivative antibiotics.
The pharmaceutical corporation, led by Ignasi Biosca and a member of CataloniaBio & HealthTech, has invested €10 million in the new facility, which will meet the company's current needs in the national and international markets and allow it to enter the United States market in 2019.
The event, on 23 October, featured President of Spain Pedro Sánchez, President of Castile-La Mancha Emiliano García-Page, Mayor of Toledo Milagros ...
6 November 2018
Laboratorios Rubió has invested €4 million in its factory in Castellbisbal (Barcelona) with its sights set on the United States, according to newspaper La Vanguardia. The pharmaceutical corporation led by Pelayo Rubió produces 6 million units of its drugs each year.
"We hope to market our products in North America by 2020," said Pelayo Rubió.
The company saw revenue of €30.7 million in 2017, up 20% from 2016, and is present in 47 countries.
We recommend this video of CataloniaBio & HealthTech interviewing Pelayo Rubió:
2 November 2018
Lit-Control® is the world's first digital therapeutics solution that allows the most common urological diseases to be prevented and treated effectively from home while also improving patients' adherence to the treatment.
“We're excited to work with Exeltis to expand the use of Lit-Control® and provide a response to the uncovered medical needs in the area of urology thanks to the constant work with the scientific-medical community and patients” says Rosendo ...
30 October 2018
The biomedical industry entrepreneur Antonio Parente has joined the Specipig board of directors as an independent member. Parente will combine this position with his roles on the governing bodies of GP Pharm and BCN Peptides.
Parente's experience will be key in the Catalan company's international consolidation phase, five years after it was founded. Specipig is the only company in the whole of Europe to offer the whole process from pig breeding to CRO services for biomedical research. 80% of its turnover is already from other countries.
Dr Parente was a founder of CataloniaBio, and in 2010 and 2014 was president ...
29 October 2018
Oryzon Genomics, a CataloniaBio & HealthTech member, announced the successful closure of the subscription of a capital increase of 13 million euros through ordinary shares. The offering included corporate investors specialized in healthcare and life sciences from the USA and Europe.
On the other hand, the biopharmaceutical company started the inclusion of the first patient in a Phase IIa clinical trial with Iadademstat (ORY-1001) in elderly Acute Myeloid Leukemia (AML). The study named ALICE (AML trial with LSD1i in Combination with azacitidine in the Elderly) is conducted at two Spanish hospitals, La Fe in Valencia and Vall d'Hebron in Barcelona ...
26 October 2018
Aelix Therapeutics, a CataloniaBio & HealthTech member, and Gilead Sciences Inc. have entered into collaboration to jointly evaluate proprietary research products in a strategic clinical study aimed at achieving a functional cure for HIV.
The collaboration will allow them to conduct clinical study Aelix-003 to assess the safety, tolerability, immunogenicity and efficacy of a regimen of the Aelix HTI T-cell vaccine and the Gilead Toll-Like Receptor 7 agonist vesatolimod in HIV-infected individuals already on antiretroviral therapy. The Aelix-003 trial is expected to begin in early 2019.
Aelix Therapeutics has its headquarters at the Barcelona Science Park.
Photo: Dr ...